Proteinase inhibitor / zhubný nádor

Nucleic acids encoding chimeric proteins comprising BMP-2 and a proteinase inhibitor

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

CROSS REFERENCE TO RELATED APPLICATIONS This application is a 35 U.S.C. .sctn.371 National Phase Entry Application from PCT/DE01/01510, filed Apr. 18, 2001 and designating the United States. This application further claims foreign priority to German application DE 100 20 125.3, filed Apr. 18,

4-substitued-3-[1 or 2 amino acid residue]-azetidin-2-one derivatives useful as cysteine proteinase inhibitor

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND OF INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986, 122,

Prostate specific antigen (PSA)-proteinase inhibitor complexes

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND OF THE INVENTION The prostate specific antigen (PSA) was first purified from prostatic tissue (Wang et al. Invest Urol 1979), but the same protein was almost simultaneously and independently characterized in the seminal plasma (Hara et al. J Lab Clin Med 1989; Graves et al. N Engl J Med

CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

STATEMENT REGARDING SEQUENCE LISTING The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is

Therapeutic use for ALPHA1 proteinase inhibitor in hematopoiesis

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 15, 2012, is named 86519CON.txt and is 11,216 bytes in size. BACKGROUND OF THE

Therapeutic use for .alpha..sub.1 proteinase inhibitor in hematopoiesis

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND OF THE INVENTION Full length active .alpha..sub.1 proteinase inhibitor (.alpha..sub.1PI, .alpha..sub.1 antitripsin) is composed of 394 amino acids (aa) having a mass of approximately 55 kDa when fully glycosylated (Berninger, 1985). Hepatocytes are the primary source of .alpha..sub.1PI,

Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The present invention relates to compounds that are inhibitors of cysteine proteinases, pharmaceutical compositions containing said compounds, and their use in therapy. More specifically, but not exclusively, the invention relates to compounds that are inhibitors of cathepsin K and related cysteine

Furo[3,2-B] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The present invention relates to compounds that are inhibitors of cysteine proteinases, pharmaceutical compositions containing said compounds, and their use in therapy. More specifically, but not exclusively, the invention relates to compounds that are inhibitors of cathepsin K and related cysteine

Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The present invention relates to compounds that are inhibitors of cysteine proteinases, pharmaceutical compositions containing said compounds, and their use in therapy. More specifically, but not exclusively, the invention relates to compounds that are inhibitors of cathepsin K and related cysteine

Assay of free and complexed prostate-specific antigen (PSA)

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The present invention relates to an immunoassay of prostate-specific antigen (PSA), in which specific reagent materials (antibodies) are used that allow the measurement of free PSA as well as the PSA proteinase inhibitor complex. It also relates to the use of free PSA and the PSA proteinase

3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND OF THE INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,

4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND OF THE INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,

4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND OF THE INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,

Assay of free and complexed prostate-specific antigen

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The present invention relates to an immunoassay of prostate-specific antigen (PSA), in which specific reagent materials (antibodies) are used that allow the measurement of free PSA as well as the PSA proteinase inhibitor complex. It also relates to the use of free PSA and the PSA proteinase

Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

FIELD OF THE INVENTION The present invention relates to methods and compositions for the inhibition of cellular proliferation. More particularly, the present invention relates to the use of tissue factor pathway inhibitor proteins or peptides, and active fragments thereof, for inhibiting

proteinase inhibitor/zhubný nádor

Nucleic acids encoding chimeric proteins comprising BMP-2 and a proteinase inhibitor

4-substitued-3-[1 or 2 amino acid residue]-azetidin-2-one derivatives useful as cysteine proteinase inhibitor

Prostate specific antigen (PSA)-proteinase inhibitor complexes

CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer

Therapeutic use for ALPHA1 proteinase inhibitor in hematopoiesis

Therapeutic use for .alpha..sub.1 proteinase inhibitor in hematopoiesis

Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors

Furo[3,2-B] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors

Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors

Assay of free and complexed prostate-specific antigen (PSA)

3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators

4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators

4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators

Assay of free and complexed prostate-specific antigen

Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments

Najkompletnejšia databáza liečivých bylín podporovaná vedou